Longeveron says Phase 2b trial shows laromestrocel improves physical condition in age-related frailty patients
LGVN•Longeveron said Phase 2b results showed laromestrocel improved physical condition in age-related frailty patients versus placebo; the findings were published in February 2026. The company also reported a $1 million XPRIZE Healthspan award and an Alzheimer’s study analysis posted as a preprint.
1. Trial and research updates
Longeveron highlighted Phase 2b results showing its laromestrocel cell therapy improved physical condition in age-related frailty patients versus placebo; the findings were published in February 2026. A new exploratory analysis from the company’s Phase 2a Alzheimer’s study was posted as a preprint and indicated reduced brain inflammation with treatment, but has not been peer reviewed. Longeveron received a $1 million XPRIZE Healthspan Milestone 2 award to support a future competition clinical trial.
